Session » Pediatric Rheumatology – Clinical Poster II: Autoinflammatory Disorders, Scleroderma, and Miscellaneous

Date: Monday, October 22, 2018

Time: 9:00AM-11:00AM

Meeting: 2018 ACR/ARHP Annual Meeting

9:00AM-11:00AM: Abstract Number: 1427

A New Model of Care for Pediatric Rheumatology in Ontario: Preliminary Results from Pilot Telemedicine Clinics Utilizing Advanced Clinician Practitioners in Arthritis Care

9:00AM-11:00AM: Abstract Number: 1429

A Quality Update: Improved Transfer Time Among Rheumatology Patients Transferring from Pediatric to Adult Care at an Academic Medical Center

9:00AM-11:00AM: Abstract Number: 1412

A Systematic Literature Review of Efficacy and Safety of Current Therapies for the Treatment of Hyperimmunoglobulinemia D Syndrome and TNF Receptor-Associated Periodic Syndrome

9:00AM-11:00AM: Abstract Number: 1424

After 24 Months Observation Period the Patients Related Outcomes Improve Significantly in the Juvenile Scleroderma Inceptions Cohorte

9:00AM-11:00AM: Abstract Number: 1423

Autoantibody Testing in Pediatric Localized Scleroderma (LS)

9:00AM-11:00AM: Abstract Number: 1415

Emapalumab, an Anti-Interferon Gamma Monoclonal Antibody in Two Patients with NLRC4-Related Disease and Severe Hemophagocytic Lymphohistiocytosis (HLH)

9:00AM-11:00AM: Abstract Number: 1432

Engaging Patients and Parents to Improve Mental Health for Youth with Rheumatologic Disease

9:00AM-11:00AM: Abstract Number: 1421

Evaluating the Validity of SIX-Minute Walk Test in Juvenile Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 1418

External Validation of the Autoinflammatory Disease Activity Index (AIDAI) in Patients with Colchicine-Resistant FMF, Hids/Mkd, and TRAPS: Results from a Pivotal, Phase 3 Trial of Canakinumab

9:00AM-11:00AM: Abstract Number: 1417

Hemophagocytic Lymphohistiocytosis (HLH) Mimickers: CXCL9 As a Potential Biomarker Distinguishing HLH from Other Hyperferritinemic Syndromes

9:00AM-11:00AM: Abstract Number: 1435

Hormonal Contraception Use and Capacity to Self-Screen for Contraindications Among Adolescents in a Pediatric Rheumatology Clinic

9:00AM-11:00AM: Abstract Number: 1422

Impact of Juvenile Localized Scleroderma on Longitudinal Quality of Life

9:00AM-11:00AM: Abstract Number: 1431

Kikuchi-Fujimoto Disease: A Retrospective Analysis of 23 Pediatric Cases from a US Center

9:00AM-11:00AM: Abstract Number: 1419

Long-Term Outcome of 50 Patients with Linear Scleroderma Treated with Methotrexate

9:00AM-11:00AM: Abstract Number: 1411

Long-Term Safety of Different Doses of Canakinumab (<2, 2–<4, and 4–<8 mg/kg) in Patients Aged <4–≥65 Years: Results from the β-Confident Registry

9:00AM-11:00AM: Abstract Number: 1428

Parental Involvement and Adolescents/Young Adults Self-Management during the Transition Period: A Cross-Sectional Survey in Childhood Onset Rheumatic Diseases

9:00AM-11:00AM: Abstract Number: 1434

Patient-Proxy Agreement on Health-Related Quality of Life in Juvenile Fibromyalgia Syndrome

9:00AM-11:00AM: Abstract Number: 1414

Pharmacovigilance of Biologics for Systemic Juvenile Idiopathic Arthritis Patients By the German Biologics Registry

9:00AM-11:00AM: Abstract Number: 1436

Pregnancy Outcomes in Partners of DMARD Exposed Men with Juvenile Idiopathic Arthritis – an Observational Study

9:00AM-11:00AM: Abstract Number: 1420

Prospective Validation of Cone Beam Computed Tomography for the Assessment of Disease Progression in Linear Scleroderma of the Face

9:00AM-11:00AM: Abstract Number: 1430

Research Priorities for Addressing Mental Health Needs of Pediatric Patients with Rheumatologic Disease

9:00AM-11:00AM: Abstract Number: 1416

Risk Score of Macrophage Activation Syndrome in Patients with Systemic Juvenile Idiopathic Arthritis

9:00AM-11:00AM: Abstract Number: 1413

Safety of Tocilizumab in Patients Aged <2 Years with Active Systemic Juvenile Idiopathic Arthritis Treated for One Year

9:00AM-11:00AM: Abstract Number: 1433

The Role of Patient and Parental Resilience in Amplified Musculoskeletal Pain Syndrome

9:00AM-11:00AM: Abstract Number: 1426

The Utilization of S100 Proteins Testing in Pediatric Rheumatology Patients in a Tertiary Care Institution and Implications for Care

9:00AM-11:00AM: Abstract Number: 1438

Treatment and Response of Down Syndrome Arthropathy

9:00AM-11:00AM: Abstract Number: 1425

Update from the Juvenile Scleroderma Inception Cohort

9:00AM-11:00AM: Abstract Number: 1437

Use,Safety and Efficacy of Thalidomide from a Tertiary Level Pediatric Rheumatology Centre in India

9:00AM-11:00AM: Abstract Number: 1439

Yellow Fever Vaccination in Brazil: Short-Term Safety in Pediatric Autoimmune Rheumatic Diseases

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].